If you were trying to figure out what moved markets in 2025, you could do worse than following the executive order tracker at the White House. President Trump spent the year reshaping entire industries through a combination of deregulation and old-school protectionism, creating winners and losers across crypto, drones, and healthcare in ways that felt more like industrial policy than typical Republican orthodoxy.
The strategy was straightforward: deregulate the stuff you want to grow domestically, wall off foreign competition, and let capital flow accordingly. The result? A year of sharp sector rotations and genuine policy-driven volatility that actually mattered to stock prices.
The Crypto Capital Play
In late January 2025, the administration made its move to position the U.S. as what they called the "crypto capital of the planet." Trump's Digital Financial Technology executive order did two big things: it established a national digital asset stockpile (yes, the government is now HODLing) and created a federal framework for stablecoins, which had been operating in regulatory limbo for years.
The market reaction was immediate. Bitcoin (BTC) pushed above $100,000 for the first time, and crypto-adjacent equities rode the wave. Coinbase Global, Inc. (COIN) and Strategy, Inc. (MSTR) saw massive capital inflows as the regulatory environment flipped from hostile to friendly practically overnight. When the government goes from "we might ban this" to "we're building a strategic reserve," that's a pretty clean signal for institutional money sitting on the sidelines.
Drones Get Their Moment
On June 6, Trump signed two executive orders with very on-brand names: "Unleashing American Drone Dominance" and "Restoring American Airspace Sovereignty." The substance was equally straightforward: a strict "buy American" mandate for all federal drone purchases and an outright ban on foreign-manufactured drones (read: Chinese) in critical infrastructure.
But the real unlock came from the FAA directive. The administration ordered the agency to fast-track beyond visual line of sight regulations, which had been stuck in bureaucratic purgatory for years. BVLOS is the holy grail for commercial drones because it enables long-range delivery and industrial inspection at scale. Without it, you're basically flying expensive toys.
Investors poured capital into the pure-play drone stocks. AeroVironment, Inc. (AVAV) and Red Cat Holdings, Inc. (RCAT) rallied through the summer, while Axon Enterprise, Inc. (AXON) hit all-time highs as they integrated NDAA-compliant drone swarms into public safety contracts. The cherry on top came December 22, when the administration announced plans to procure 300,000 low-cost attritable drones for the Pentagon. That's not a typo. Three hundred thousand drones. The sector went from niche tech play to legitimate defense and logistics powerhouse in less than a year.
Healthcare's Wild Ride
If crypto and drones were about unleashing growth, healthcare was about controlled chaos. The Trump administration spent 2025 issuing executive orders aimed at radically lowering drug costs and reshuffling domestic supply chains, and the sector whipsawed accordingly.
On May 5, Trump signed an order granting regulatory relief for domestic medicine production, accelerating permitting for U.S.-based manufacturing. That was the carrot. Then came the stick.
On May 12, Trump signed the favored-nation pricing executive order, which sent shockwaves through biopharma. The policy linked U.S. prescription drug prices to the lowest costs paid in other developed nations. If you're a pharma executive used to charging U.S. patients multiples of what Europeans pay, this is your nightmare scenario. The pricing power that funded R&D budgets suddenly looked vulnerable.
But the story got more nuanced by year-end. Eli Lilly And Co. (LLY) and Novo Nordisk A/S (NVO) saw significant activity after cutting high-profile deals to offer GLP-1 medications through the administration's TrumpRx platform. Turns out there's money to be made even in a price-controlled environment if you're selling the hottest drugs in the world and the government is helping distribute them.
Meanwhile, health insurance giants got squeezed from the other direction. UnitedHealth Group Inc. (UNH) dropped nearly 10% in a single day in December after Trump signaled a mandate for insurers to ease up on premiums. When you're simultaneously capping drug prices and squeezing insurance margins, you're essentially trying to redistribute healthcare economics in real time. The volatility reflected genuine uncertainty about who wins and loses in that reshuffle.
The New Industrial Policy
What tied these moves together was a coherent, if unconventional, framework: aggressive deregulation for domestic industries paired with protectionist barriers against foreign competition. It's not exactly free-market capitalism, but it's not traditional Democratic industrial policy either. Call it state-backed sector selection.
The blend of pro-growth deregulation and aggressive price intervention made healthcare one of the most actively traded sectors of 2025, while crypto and drones emerged as legitimate growth stories backed by federal policy rather than just venture capital hype. Whether you liked the politics or not, the market impact was undeniable. Trump moved stocks in 2025 not through tweets or tariff threats, but through executive orders that fundamentally reshaped regulatory frameworks. And investors who paid attention to the policy details made money.
